文献速递神经眼科

Leber遗传性视神经病变的基因治疗:低剂量与中剂量视觉结果

Gene Therapy for Leber Hereditary Optic Neuropathy: Low- and Medium-Dose Visual Results.
PubMed 文献 · Ophthalmology · 2017-06-21

这项前瞻性开放标签研究对14例G11778A线粒体DNA突变的Leber遗传性视神经病变患者单眼玻璃体内注射AAV2(Y444,500,730F)-P1ND4v2,低中剂量下治疗眼12个月视力平均改善0.24 logMAR,对侧眼改善0.09 logMAR;治疗眼颞侧视网膜神经纤维层厚度未见变薄,2例出现无症状葡萄膜炎且未经治疗自行消退。

要点

  • 低中剂量异位基因治疗在Leber遗传性视神经病变中似乎安全,未损害颞侧视网膜神经纤维层。
  • 治疗眼12个月视力平均改善0.24 logMAR,对侧眼改善0.09 logMAR。
  • 2例出现无症状葡萄膜炎,未经治疗自行消退。

核心结论

  • 低剂量与中剂量异位基因治疗对Leber遗传性视神经病变似乎安全,不损害颞侧视网膜神经纤维层,为下一步测试高剂量打开大门。

研究设计与样本

  • 前瞻性开放标签研究,每位受试者单眼单次玻璃体内注射AAV2(Y444,500,730F)-P1ND4v2。
  • 共14例有视力丧失且携带G11778A线粒体DNA突变的患者;组1为6例双眼慢性视力丧失超过12个月者,组2为6例双眼视力丧失少于12个月者,组3为2例单眼视力丧失者。
  • 9例患者随访至少12个月;采用广义估计方程进行纵向分析。

主要发现

  • 组1和组2治疗眼12个月视力较基线平均改善0.24 logMAR,对侧眼改善0.09 logMAR。
  • 事后比较显示,组2患者12个月时研究眼减对侧眼改善差值0.53 logMAR,大于既往急性自然病史患者的0.21 logMAR(P=0.053)。
  • 18个月时,组2基因治疗患者研究眼减对侧眼改善差值0.96 logMAR,大于既往急性自然病史患者的0.17 logMAR(P<0.001)。
  • 治疗眼颞侧视网膜神经纤维层厚度注射前平均54 μm、12个月55 μm;对侧眼注射前56 μm、12个月降至50 μm(P=0.013)。
  • 广义估计方程提示治疗眼PERG振幅较对侧眼恶化约0.05 μV(P=0.009,exchangeable);其他视觉功能指标双眼间未见明显差异。

关键数值与推荐

  • 14例患者中组1为6例双眼慢性视力丧失超过12个月者,组2为6例双眼视力丧失少于12个月者,组3为2例单眼视力丧失者。
  • 治疗眼12个月视力平均改善0.24 logMAR,对侧眼改善0.09 logMAR。
  • 组2患者12个月研究眼减对侧眼改善差值0.53 logMAR,既往急性自然病史患者为0.21 logMAR(P=0.053)。
  • 组2患者18个月研究眼减对侧眼改善差值0.96 logMAR,既往急性自然病史患者为0.17 logMAR(P<0.001)。
  • 治疗眼颞侧视网膜神经纤维层厚度54 μm至55 μm,对侧眼56 μm至50 μm(P=0.013)。

临床怎么用

  • 原文结论认为低中剂量异位基因治疗似乎安全且不损害颞侧视网膜神经纤维层,为下一步测试高剂量打开大门。

局限性

  • 2例患者出现无症状葡萄膜炎,未经治疗自行消退。
  • 广义估计方程提示治疗眼PERG振幅较对侧眼恶化约0.05 μV(P=0.009,exchangeable)。
  • 原文结论提出低中剂量结果可为下一步测试高剂量打开大门。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine the effects of AAV2(Y444,500,730F)-P1ND4v2 in patients with Leber hereditary optic neuropathy (LHON). DESIGN: Prospective open-label, unilateral single-dose, intravitreal injection of AAV2(Y444,500,730F)-P1ND4v2 per participant. PARTICIPANTS: Fourteen patients with visual loss and mutated G11778A mitochondrial DNA. METHODS: Intravitreal injection with the gene therapy vector AAV2(Y444,500,730F)-P1ND4v2 into 1 eye. Six participants with chronic bilateral visual loss lasting more than 12 months (group 1), 6 participants with bilateral visual loss lasting less than 12 months (group 2), and 2 participants with unilateral visual loss (group 3) were treated. Nine patients had at least 12 months of follow-up. Clinical testing included visual acuity, visual fields, optical coherence tomography, pattern electroretinography, and neuro-ophthalmic examinations. Generalized estimating equation methods were used for longitudinal analyses. MAIN OUTCOME MEASURE: Loss of visual acuity. RESULTS: For groups 1 and 2, month 12 average acuity improvements with treatment relative to baseline were 0.24 logarithm of the minimum angle of resolution (logMAR). Fellow eyes had a 0.09-logMAR improvement. A post hoc comparison found that at month 12, the difference between study eye minus fellow eye improvement in group 2 patients of 0.53 logMAR was greater than that observed in our prior acute natural history patients of 0.21 logMAR (P = 0.053). At month 18, the difference between study eye minus fellow eye improvement in our acute group 2 gene therapy patients of 0.96 was more than that observed in our prior acute natural history patients (0.17 logMAR; P < 0.001). Two patients demonstrated asymptomatic uveitis that resolved without treatment. Optical coherence tomography of treated eyes showed an average temporal retinal nerve fiber layer thickness of 54 μm before injection and 55 μm at month 12. For fellow eyes before injection, it was 56 μm, decreasing to 50 μm at month 12 (P = 0.013). Generalized estimating equations suggested that PERG amplitudes worsened more in treated eyes than in fellow eyes by approximately 0.05 μV (P = 0.009 exchangeable). No difference between eyes in outcomes of other visual function measures was evident. CONCLUSIONS: Allotopic gene therapy for LHON at low and medium doses seems to be safe and does not damage the temporal retinal nerve fiber layer, opening the door next for testing of the high dose.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Guy J, Feuer WJ, Davis JL, et al. Gene Therapy for Leber Hereditary Optic Neuropathy: Low- and Medium-Dose Visual Results. Ophthalmology. 2017. PMID: 28647203. doi:10.1016/j.ophtha.2017.05.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。